so, the same re-hashed things they say with every oil stock on every cc?
So, the same rehashed bashes on every oil mb? Aren't you due over on the KOG board? Get a clue ... it ain't a sprint, it's a marathon!!
It's funny, actually. Some get scared into covering pretty easily when we gain any traction. Nice volume and green yesterday, so let's throw a large block out there on the open to dissuade any buyers and then we'll keep the pressure on with 100-500 block sells throughout the a.m. Tick tock ...
Don't you worry your little head about Kitty ... and just in case you do, the cost basis for those shares is well under our current level!
And to think our quiet little pond has now turned into a cesspool! Yuck!!
Gee, I bet all the analysts and institutions buying over $10 missed that Pen! Thanks!!!
Not sure, but I think it would be highly unlikely for any developmental stage biotech to buy back shares. It isn't seen as a wise use of capital, for the most part. Our share structure is fine, once revenue kicks in. If I were a betting person, I think we'd see more shares issued before any hopes of reducing the share count. That isn't always a negative if raising cash is being done for the right reasons. Look at MDXG today ... share offering and they're not down much at all. All about market perception. Of course, IF shares were issued we KNOW the resident shorts would have a field day predicting gloom and doom!
With all of the recent short articles, all I can say is it smacks of desperation!
Actually, pelo, if we're being realistic, TSRX did not behave like this. We got sold down from about $8 to $6.50 area and then never really looked back until we were in the $11 range. Right now, the market knows there is some down time here and ACRX has always been susceptible to low volume pressure, both ways. I plan to take advantage of the pressure, but I'm not jumping in with both feet as I've watched this happen before. I've got enough shares that IF something really positive happens, I'll be happy. But, if you are accumulating new shares or adding, do it incrementally, and take the emotion out of it. Risk/reward favors being long here! GLTY
Ah, WinGOAT ... I was here LONG before you ever heard about KOG. I just check in once awhile to see the fresh crop of Neanderthals that find their way here. First buys for me were in the sub .60 range! You?
Still think that the short thesis is backward looking. Yes, in the past ... but things have changed. Don't they believe in turnaround stories? How can the analysts be less than informed than these naysayers? What about the institutional investors that are climbing onboard? I guess you either "believe", or you don't.
Talk to those that bought MU around $7 this year! Yowza!!!
Not really a negative, imo. Only 5% dilution and they needed cash.
Really humorous to read and re-read the bashers prognostications. They've been the same since the $1 level. Wash, rinse, repeat ...these "experts" will disappear soon enough, too.
And, why would he say our margins are below industry average ... revenue to be below est. next qtr? Does he think all of our new hires will be twiddling their thumbs? Sounds to me like he is looking at historical data and, obviously, does not know the story here. Or, is he simply covering his #$%$ from the sell rating he had on the stock after learning how ludicrous THAT was? Lazy is right!
◾ The gross profit margin for OSIRIS THERAPEUTICS INC is currently extremely low, coming in at 1.67%. Despite the low profit margin, it has increased significantly from the same period last year. Despite the mixed results of the gross profit margin, OSIR's net profit margin of -24.36% significantly underperformed when compared to the industry average.
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Biosurgery and Therapeutics. Osiris has a market cap of $521.6 million and is part of the health care sector and drugs industry. Shares are up 64.4% year to date as of the close of trading on Friday
Bull hockey ...
NEW YORK (TheStreet) -- Osiris Therapeutics (Nasdaq:OSIR) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including poor profit margins and feeble growth in the company's earnings per share.
Highlights from the ratings report include:
◾ OSIR's very impressive revenue growth greatly exceeded the industry average of 11.4%. Since the same quarter one year prior, revenues leaped by 219.9%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
◾ OSIR's debt-to-equity ratio is very low at 0.01 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 4.57, which clearly demonstrates the ability to cover short-term cash needs.
◾ Compared to other companies in the Biotechnology industry and the overall market, OSIRIS THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
◾ OSIRIS THERAPEUTICS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, OSIRIS THERAPEUTICS INC swung to a loss, reporting -$0.13 versus $0.44 in the prior year. For the next year, the market is expecting a contraction of 76.9% in earnings (-$0.23 versus -$0.13).
Well, you rely on some journalists for your short thesis. I prefer to look at the caliber of the institutional investors who have place large "long" $$ here, along with the analysts covering the stock ... Reiterations of buys and raised price targets. In addition, the contracts being signed are with the top echelon of pharma. Still like my risk reward!!
Also, the only negative "reports" are the SA articles, not any analyst coverage. So, I suggest you take THAT with a grain of salt, too!
It goes both ways ... I can appreciate some skepticism. However, if you put the puzzle pieces together (the string of signed agreements/deals coming in), you certainly have to see an improved picture, no?
Or, let's do the math for our short "experts" ... that's over 200% increase! I like the risk/reward!
Have a good weekend!